The company will transfer part of its licensed woman’s diagnostic and treatment products to another company including additional territories and provides update on its Alliance joint venture partnership.
TORONTO, ON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals (OTC: EAPH), announces it has initiated discussions to transfer part of its licensed woman’s diagnostic and treatment products to another company including additional territories and provides update on its Alliance joint venture partnership.
On the heels of Easton’s and its partner BMV Medica’s recently announced sub distribution agreement with BAYER and the legal entity for their subsidiary company, Bayer Consumer Care AG for product VS-Sense, Easton / BMV have entered into negotiations with a possible new distribution partner for one of its other licensed products and additional territories. NDA’s have been executed with hopes for any finalized agreements to include an upfront cash payment and recurring royalties similar to its sub-distribution agreement reached with BAYER for product VS-Sense.
Easton / BMV currently have 3 products launched following the previous two product launches with its sub distribution partner, Gedeon Richter Plc and their Mexican subsidiary company for “Gynofit” and AmnioSense”. In addition, Easton’s sub-distribution partner, Windsor Pharmaceuticals from Panama, has received approval for all products with sales status updates pending.
As a result of the closed agreement with BAYER AG, Easton is nearing completed discussions with BMV Medica SA to acquire 100% of BMV and other products that they currently possess and / or have licensing rights towards.
In other news, 1124123 Ontario Limited (o/a - Alliance Group) has had to delay its operations launch on its aggregate business to an anticipated mid March launch due to extreme weather conditions. Construction of facilities such as greenhouses for the cultivation of medical marijuana have also been delayed due to shortages and backlogs from manufacturers who specialize in these types of facilities. Although Alliance believes it has received an LP license exemption to grow marijuana to meet demand on the expected launch of medical / recreational marijuana in Canada later this summer, Easton / Alliance have received proposals and are nearing an expected agreement to proceed with its own LP application to become a legal grower on its 135 acres of property, part of which is zoned for agricultural use. More detailed updates are soon to be announced.
Woman’s Products Overview:
VS-Sense - VagiSense: is the current brand name of the BV (Bacterial Vaginosis) patented diagnostic test. VagiSense (VS-Sense) is the same product Bayer Pharmaceuticals had licensed and launched in late 2015 in Europe under its brand, Canestest. Prestige Distribution is currently selling in the US under its brand, Monistat, with multi-million dollars in sales and growing.
Gynofit: European-Union approved natural treatment for Bacterial Vaginosis (BV), potentially eliminating the use of antibiotics in women with BV and promoting optimal vaginal health. BV is expected to affect the vast majority of women at some point in their lives.
AmnioSense: patented amniotic fluid leak test is a unique Point-of-Care diagnostic panty liner for women in late-stage pregnancy able to distinguish between urine and amniotic fluid (breaking of water).
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica and together own the exclusive distribution rights in Mexico and Latin America for patented women’s diagnostic / treatment products and two generic cancer drugs. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts. Easton has closed on an agreement to acquire a 50% ownership stake on a 135 acre property located in Georgina Township and 2 businesses on that property including medical / recreational marijuana.
For More Information On Easton Visit:
http://www.eastonpharmaceuticalsinc.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Evan Karras / CEO / President Tel: +1(416) 619-0291 Tel: +1(347) 284-0192 Email: info@eastonpharmaceuticalsinc.com
